Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers.

Zhu HJ, Patrick KS, Straughn AB, Reeves OT 3rd, Bernstein H, Shi J, Johnson HJ, Knight JM, Smith AT, Malcolm RJ, Markowitz JS.

J Clin Psychopharmacol. 2017 Aug;37(4):419-428. doi: 10.1097/JCP.0000000000000721.

2.

Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder.

Sayer GR, McGough JJ, Levitt J, Cowen J, Sturm A, Castelo E, McCracken JT.

J Child Adolesc Psychopharmacol. 2016 Dec;26(10):882-888. Epub 2016 Aug 2.

3.

Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate.

Patrick KS, Straughn AB.

Drug Metab Dispos. 2016 Mar;44(3):418-21. doi: 10.1124/dmd.115.067975. Epub 2016 Jan 4.

4.

Comparative Ethanol-Induced Potentiation of Stimulatory Responses to Dexmethylphenidate Versus Methylphenidate.

Patrick KS, Straughn AB, Reeves OT 3rd, Bernstein H, Malcolm R.

J Clin Psychopharmacol. 2015 Aug;35(4):464-7. doi: 10.1097/JCP.0000000000000348.

5.
6.

Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder.

Stein MA, Waldman I, Newcorn J, Bishop J, Kittles R, Cook EH Jr.

J Child Adolesc Psychopharmacol. 2014 Jun;24(5):238-44. doi: 10.1089/cap.2013.0102. Epub 2014 May 9.

7.

Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.

Silva RR, Brams M, McCague K, Pestreich L, Muniz R.

Clin Neuropharmacol. 2013 Jul-Aug;36(4):117-21. doi: 10.1097/WNF.0b013e31829aa92c.

PMID:
23860345
8.

Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release.

Roesch B, Corcoran M, Haffey M, Stevenson A, Wang P, Purkayastha J, Martin P, Ermer J.

Drugs R D. 2013 Mar;13(1):53-61. doi: 10.1007/s40268-013-0009-5.

9.

A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.

Brams M, Turnbow J, Pestreich L, Giblin J, Childress A, McCague K, Muniz R.

J Clin Psychopharmacol. 2012 Oct;32(5):637-44. doi: 10.1097/JCP.0b013e3182677825. Erratum in: J Clin Psychopharmacol. 2012 Dec;32(6):766.

PMID:
22926597
10.

Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane.

Spencer TJ, Bonab AA, Dougherty DD, Mirto T, Martin J, Clarke A, Fischman AJ.

J Clin Psychiatry. 2012 Mar;73(3):346-52. doi: 10.4088/JCP.10m06393. Epub 2011 Nov 1.

PMID:
22154896
11.

Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.

Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, Newcorn JH.

J Child Adolesc Psychopharmacol. 2011 Dec;21(6):581-8. doi: 10.1089/cap.2011.0018. Epub 2011 Dec 2.

12.

Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder.

Lyon GJ, Samar SM, Conelea C, Trujillo MR, Lipinski CM, Bauer CC, Brandt BC, Kemp JJ, Lawrence ZE, Howard J, Castellanos FX, Woods D, Coffey BJ.

J Child Adolesc Psychopharmacol. 2010 Aug;20(4):283-9. doi: 10.1089/cap.2010.0032.

13.

Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.

Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z, Manning D.

J Pain Symptom Manage. 2009 Nov;38(5):650-62. doi: 10.1016/j.jpainsymman.2009.03.011.

PMID:
19896571
14.

Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.

Childress AC, Spencer T, Lopez F, Gerstner O, Thulasiraman A, Muniz R, Post A.

J Child Adolesc Psychopharmacol. 2009 Aug;19(4):351-61. doi: 10.1089/cap.2009.0007.

PMID:
19702487
15.

Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.

Adler LA, Spencer T, McGough JJ, Jiang H, Muniz R.

J Atten Disord. 2009 Mar;12(5):449-59. doi: 10.1177/1087054708320397.

PMID:
19218542
16.

A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.

Brams M, Muniz R, Childress A, Giblin J, Mao A, Turnbow J, Borrello M, McCague K, Lopez FA, Silva R.

CNS Drugs. 2008;22(8):693-704.

PMID:
18601306
17.

Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.

Muniz R, Brams M, Mao A, McCague K, Pestreich L, Silva R.

J Child Adolesc Psychopharmacol. 2008 Jun;18(3):248-56. doi: 10.1089/cap.2007.0015.

PMID:
18582179
19.

Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue.

Lower EE, Harman S, Baughman RP.

Chest. 2008 May;133(5):1189-95. doi: 10.1378/chest.07-2952. Epub 2008 Feb 8.

PMID:
18263672
20.

Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.

Tuerck D, Wang Y, Maboudian M, Wang Y, Sedek G, Pommier F, Appel-Dingemanse S.

Int J Clin Pharmacol Ther. 2007 Dec;45(12):662-8.

PMID:
18184535

Supplemental Content

Loading ...
Support Center